Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents

International Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 741-747

  Tunggal, Jonathan K ^a   Ballinger, James R ^b   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b University Medical Imaging Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DENSITY; CHO CELL; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; DRUG UPTAKE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; CELL COUNT; CELL SURVIVAL; CHO CELLS; COLONY-FORMING UNITS ASSAY; CRICETINAE; CYCLOSPORINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; P-GLYCOPROTEINS; TECHNETIUM TC 99M SESTAMIBI; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032957644     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990531)81:5<741::AID-IJC13>3.0.CO;2-G     Document Type: Article

References (21)

1. ARVELO, F., POUPON, M.F., BICHAT, F., GROSSIN, F., BOURGEOIS, Y., JACROT, M., BASTIAN, G., and LE CHEVALIER, T., Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Europ. J. Cancer, 31A, 1862-1868 (1995).
2. 99mTc-SestaMIBI as an agent for imaging P-glycoprotein mediated multidrug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl. Med. Comm., 16, 253-257 (1995).
3. BOYER, M.J, HORN, I., FIRESTONE, R.A., STEELE-NORWOOD, D., and TANNOCK, I.F., pH dependent cytotoxicity of N-dodecylimidazole: a compound that acquires detergent properties under acidic conditions Brit. J. Cancer, 67, 81-87 (1993).
4. DALTON, W.S., CROWLEY, J.J., and SALMON, S., A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group Study. Cancer, 75, 815-820 (1995).
5. DURAND, R.E., Distribution and activity of antineoplastic drugs in a tumor model. J. nat. Cancer Inst., 81, 145-152 (1989).
6. ENDICOTT, J.A., and LING, V., The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem., 58, 137-171 (1989).
7. FOJO, A., UEDA, K., SALMON, D.J., POPLACK, D.G., GOTTESMAN, M.M., and PASTAN, I., Expression of a multidrug-resistance gene in human tumours and tissues. Proc. nat. Acad. Sci. (Wash.), 84, 265-269 (1987).
8. IZQUIERDO, M.A., SHOEMAKER, R.H., FLENS, M.J., SCHEFFER, G.L., WU, L., PRATHER, T.R., and SCHEPER, R.J., Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer, 65, 230-237 (1996).
9. LIST, A.F., SPIER, C., GREER, J., WOLFF, S., HUTTER, DORR, J., SALMON, S.E., FUTSCHER, B., BAIER, M., and DALTON, W.S., Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. J. clin. Oncol., 11, 1652-1660 (1993).
10. LUDESCHER, C., EISTERER, W., HILBE, W., HOFMANN, J., and THALER, J., Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Brit. J. Haematol., 91, 652-657 (1995).
11. LUM, B.L., KAUBISCH, S., YAHANDA, A.M., ADLER, K.M., JEW, L., EHSAN, M.N., BROPHY, N.A., HALSEY, J., GOSLAND, M.P., and SIKIC, B.I., Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J. clin. Oncol., 10, 1635-1642 (1992).
12. MILLWARD, M.J., CANTWELL, B.M., MUNRO, N.C., ROBINSON, A., CORRIS, P.A., and HARRIS, A.L., Oral verapamil with chemotherapy for advance non-small cell lung cancer: a randomized study. Brit. J. Cancer, 67, 1031-1035 (1993).
13. MILROY, R., A randomized clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Brit. J. Cancer, 68, 813-818 (1993).
14. OLIVE, P.L., and DURAND, R.E., Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev., 13, 121-138 (1994).
15. PIWNICA-WORMS, D., CHIU, M.L., BUDDING, M., KRONAUGE, J.F, KRAMER, R.A., and CROOP, J.M., Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res., 53, 977-984 (1993).
16. SHAPIRO, A.B., FOX, K., LEE, P., YANG, Y.D., and LING, V., Functional intracellular P-glycoprotein. Int. J. Cancer, 76, 857-864 (1998).
17. SHI, T., WRIN, J., REEDER, J., LIU, D., and RING, D.B., High affinity monoclonal antibodies against P-glycoprotein. Clin. Immunol. Immunopathol., 76, 44-51 (1995).
18. SOLARY, E., CAILLOT, D., CHAUFFERT, B., CASANOVAS, R-O., DUMAS, M., MAYNADI, M., and GUY, H., Feasibility of using quinine, a potential multidrug resistance reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J. clin. Oncol., 10, 1730-1736 (1992).
19. TSURUO, T., SUGIMOTO, Y., HAMADA, H., RONINSON, I., OKUMURA, M., ADACHI, K., MORISHIMA, Y., and OHNO, R., Detection of multidrug resistance markers, P-glycoprotein, an MDR1 mRNA, in human leukemia cells. Jpn. J. Cancer Res., 78, 1415-1419 (1987).
20. VAN DE VRIE, W., JONKER, A.M., MARQUET, R.L., and EGGERMONT, A.M.M., The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. J. Cancer Res. clin. Oncol., 120, 533-538 (1994).
21. WISHART, G.C., BISSETT, D., and PAUL, J., Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. clin. Oncol., 12, 1771-1777 (1994).